DNSK International reports approval of UKONIQTM (aka Umbralisib, TGR1202, RP-5264) for the treatment of marginal zone lymphoma and follicular lymphoma.
Since 2010 DNSK has been working on several projects in oncology, immunology and diabetes.
more